The PSI and ETH Zurich Center for Radiopharmaceutical Sciences covers the full range of activities for the production and clinical testing of medicinal radiocompounds.
Scientific Highlights
A superlative milestone
PSI spin-off Araris Biotech AG achieves valuation at unicorn-level!
IMPACT for Swiss society
World leader in muons and in production of medical radionuclides: The far-reaching significance of the planned upgrade.
Dr. Chiara Favaretto has been honored with the Alavi-Mandell Award 2024
We congratulate Dr. Chiara Favaretto for the excellent research work she did during her time at the Center for Radiopharmaceutical Sciences.
The Executive Committee on Personalized Health and Related Technologies (PHRT) has supported the PROGNOSTIC translational Project with a Grant of CHF 2 million
The translational project "PROGNOSTICS", proposed by a consortium led by Prof. Roger Schibli, received CHF 2 million funding from the PHRT initiative of the ETH Domain(https://www.sfa-phrt.ch/two-clinical-trial-projects-launched-transforming-clinical-care-with-eth-technologies/). The study is being conducted with the Co-applicants Prof. Dr. med. Damian Wild at the University Hospital Basel and Prof. Dr. Nicola Aceto of the ETHZ. The consortium will test a new radiopharmaceutical developed at the Center for Radiopharmaceutical Sciences in 36 patients with advanced prostate cancer.